Fatty-acid metabolism

Scientific explanation

De novo lipogenesis, fatty-acid oxidation and lipid uptake are rewired in a tumour-type-specific way, especially in hypoxic, obese-host, or OXPHOS-dependent subsets.

Cancers where relevant

Hepatocellular carcinoma Prostate cancer Androgen-sensitive prostate cancer Kidney / renal cell carcinoma

Compounds that intersect this pathway

Statins (HMG-CoA reductase inhibitors)

Inhibit HMG-CoA reductase, depleting mevalonate-pathway isoprenoids needed for RAS/RHO prenylation and some sterol-dependent growth programmes. Observational oncology signals are mixed and not a licence to treat cancer with statins.

Evidence in mapped cancers: Clinical / Human Evidence · In Vitro · Mechanistically Plausible

Omega-3 fatty acids

EPA/DHA alter eicosanoid balance and membrane signalling. Cachexia and hypotheses exist; they are not cytotoxic oncology drugs.

Convergence partners

Other pathways that co-occur with Fatty-acid metabolism on mapped adjunct records: RAS/RAF.

This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.